Trial Profile
A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) Plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Selumetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 11 Aug 2020 Status changed from active, no longer recruiting to completed.
- 24 Feb 2020 Planned End Date changed from 1 Sep 2019 to 31 Dec 2020.
- 24 Feb 2020 Planned primary completion date changed from 1 Jun 2019 to 31 Dec 2020.